<<One can list several big-science companies where the leverage is enormous, where success will bring 20X. Anybody wants a soap box, go!>>
20X potential? Ariad? MTor, ABL good chatter in cancer circles, 100% leverage. KOSN? Tough for me to get excited about EPO-D but what about HSP90 leverage? It hits a "who's who" of kinases :-) (see kosn pr the other day).
No chance for 20X, GENE, barely above cash and possibly <1X peak sales?
You have any good ideas? I'd love to hear them.
Maybe the real 20X are below my radar or we still have further to go :-)
BTW: Anyone recall a bio ipo where existing s/h were able to sell? I didn't realize that was allowed.
Reuters
Idenix IPO priced at low end of estimated range
Wednesday July 21, 6:25 pm ET
NEW YORK, July 21 (Reuters) - Biopharmaceutical company Idenix Pharmaceuticals Inc. priced its initial public offering of 5.8 million shares at $14 per share, the low end of its expected range, the underwriter said on Wednesday.
It had filed with securities regulators to offer the shares at an estimated price of $14 to $16 per share.
The company said in an amended offering document filed with the U.S. Securities and Exchange Commission that it will sell 4.6 million shares and shareholders will sell 1.2 million shares.
The underwriters, led by Goldman, Sachs & Co. and Morgan Stanley, will have the option to buy an additional 870,000 shares to cover over-allotments.
The Cambridge, Massachusetts-based company, which is more than 50 percent owned by Swiss drugmaker Novartis AG (NOVN.VX), develops drugs for treatment of human viral and other infectious diseases.
It has applied to list its stock on the Nasdaq under the symbol "IDIX." |
